Biogen (BIIB) Expected to Announce Earnings on Friday

Biogen (NASDAQ:BIIB) is projected to issue its Q4 2025 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of $1.72 per share and revenue of $2.2147 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 6, 2026 at 8:30 AM ET.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $176.76 on Wednesday. Biogen has a 1 year low of $110.04 and a 1 year high of $190.20. The stock has a market capitalization of $25.93 billion, a P/E ratio of 16.11, a P/E/G ratio of 1.50 and a beta of 0.16. The company’s 50-day moving average is $176.41 and its 200 day moving average is $155.71. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 748 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the completion of the sale, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.18% of the stock is owned by company insiders.

Institutional Trading of Biogen

Hedge funds have recently added to or reduced their stakes in the company. Orion Porfolio Solutions LLC grew its holdings in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares in the last quarter. Caisse de depot et placement du Quebec raised its holdings in Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after purchasing an additional 499,676 shares in the last quarter. AQR Capital Management LLC raised its stake in Biogen by 30.7% during the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares in the last quarter. Alyeska Investment Group L.P. grew its stake in Biogen by 66.1% during the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock worth $118,406,000 after buying an additional 336,504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Biogen by 425.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company’s stock valued at $48,804,000 after purchasing an additional 282,084 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of research analyst reports. Jefferies Financial Group lifted their price target on shares of Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, November 28th. Oppenheimer raised their target price on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday. HSBC reissued a “reduce” rating and issued a $143.00 price objective (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Morgan Stanley boosted their price target on Biogen from $149.00 to $156.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Finally, Truist Financial lifted their target price on Biogen from $142.00 to $190.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Eleven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $192.58.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.